Agree free2nap the potential is there.
With the AML phase 1 results imminent, one needs to remember that it is of orphan status.
That is, the current phase 2 (3 by3) combined with the best fit category of the phase 1 results will determine the precision of the trial to follow.
As with all orphan drug status, the advancement into trial escalation is the advantage here.
All that is needed in these results is safety and efficacy and this little gem will shine.
